Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

Arthritis Research & Therapy

Barry I Joffe¹  Anne E Stanwix²  Patrick H Dessein² 

[1]Centre for Diabetes and Endocrinology, Johannesburg, South Africa

[2]Department of Rheumatology, Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa

关键词: rheumatoid arthritis;    osteoarthritis;    cardiovascular risk;   

Others  :  1101444
DOI  :  10.1186/ar428

 received in 2002-01-30, accepted in 2002-05-16,  发布年份 2002

【 摘 要 】

Rheumatoid arthritis (RA) patients experience a markedly increased frequency of cardiovascular disease. We evaluated cardiovascular risk profiles in 79 RA patients and in 39 age-matched and sex-matched osteoarthritis (OA) patients. Laboratory tests comprised ultrasensitive C-reactive protein (CRP) and fasting lipids. Insulin sensitivity (IS) was determined by the Quantitative Insulin Sensitivity Check Index (QUICKI) in all OA patients and in 39 of the RA patients. Ten RA patients were on glucocorticoids. RA patients exercised more frequently than OA patients (χ² = 3.9, P < 0.05). Nine RA patients and one OA patient had diabetes (χ² = 4.5, P < 0.05). The median CRP, the mean QUICKI and the mean high-density lipoprotein (HDL) cholesterol were 9 mg/l (range, 0.5–395 mg/l), 0.344 (95% confidence interval [CI], 0.332–0.355) and 1.40 mmol/l (95% CI, 1.30–1.49 mmol/l) in RA patients, respectively, as compared with 2.7 mg/l (range, 0.3–15.9 mg/l), 0.369 (95% CI, 0.356–0.383) and 1.68 mmol/l (95% CI, 1.50–1.85 mmol/l) in OA patients. Each of these differences was significant (P < 0.05). After controlling for the CRP, the QUICKI was similar in RA and OA patients (P = 0.07), while the differences in HDL cholesterol were attenuated but still significant (P = 0.03). The CRP correlated with IS, while IS was associated with high HDL cholesterol and low triglycerides in RA patients and not in OA patients. A high CRP (≥ 8 mg/l) was associated with hypertension (χ² = 7.4, P < 0.05) in RA patients. RA glucocorticoid and nonglucocorticoid users did not differ in IS and lipids (P > 0.05). Excess cardiovascular risk in RA patients as compared with OA patients includes the presence of decreased IS and HDL cholesterol in RA patients. The latter is only partially attributable to the acute phase response. The CRP, IS, HDL cholesterol, triglycerides and hypertension are inter-related in RA patients, whereas none of these relationships were found in OA patients.

【 授权许可】

   
2002 Dessein et al., licensee BioMed Central Ltd

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Banks MJ, Flint EJ, Bacon PA, Kitas GD: Prevalence, clinical expression and causes of ischaemic heart disease in rheumatoid arthritis [letter]. Ann Rheum Dis 2001, 60(suppl):S47.
• [2]del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
• [3]Wallberg-Jonsson S, Backman C, Johnson O, Karp K, Lundstrom E, Sundqvist K-G, Rantapaa-Dahlqvist S: Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001, 28:2597-2602.
• [4]Wallberg-Jonsson S, Ohman ML, Rantapaa-Dahlqvist S: The epidemiology of vascular disease in rheumatoid arthritis [letter]. Ann Rheum Dis 2001, 60(suppl):S8.
• [5]Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
• [6]Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z: The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002, 29:462-466.
• [7]Svenson KLG, Pollare T, Lithell H, Hallgren R: Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988, 37:125-130.
• [8]Timar O, Sestier F, Levy E: Metabolic syndrome X: a review. Can J Cardiol 2000, 16:779-789.
• [9]Fonseca VA: Overcoming insulin resistance and preventing cardiovascular disease in diabetes: the contribution of the thiazolidinediones. [http:/ / www.medscape.com/ Medscape/ endocrinology/ TreatmentUpdate/ 1999/ tu01/ pnt-tu01.html9/ 20/ 01] webcite
• [10]Nishimura F, Murayama Y: Periodontal inflammation and insulin resistance – lessons from obesity. J Dent Res 2001, 80:1690-1694.
• [11]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS: The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [12]Klippel JH, Weyand CM, Wortmann RL: Criteria for the classification and diagnosis of the rheumatic diseases. In In Primer on the Rheumatic Diseases.. Edited by Klippel JH, Weyand CM, Wortmann RL. Atlanta, Georgia: Arthritis Foundation; 1997:453-464.
• [13]Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
• [14]Ridker PM: High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
• [15]Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999, 26:2562-2571.
• [16]Dessein PH, Stanwix AE: Inflammatory arthritis and cardiovascular disease may share a common predisposition. Rheuma-tology 2001, 40:703-704.
• [17]Pasceri V, Yeh ETH: A tale of two diseases. Circulation 1999, 100:2124-2126.
• [18]Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134:61-71.
• [19]Silveri F, Brecciaroli D, Argentati F, Cervini C: Serum levels of insulin in overweight patients with osteoarthritis of the knee. J Rheumatol 1994, 21:1899-1902.
• [20]Sturmer T, Sun Y, Sauerland S, Zeissig I, Gunther K-P, Puhl W, Brenner H: Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. J Rheumatol 1998, 25:1827-1832.
• [21]Bjorntorp P, Holm G, Rosmond R: Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 1999, 16:373-383.
• [22]Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B, Pedreno J, Vallve JC, Benito P, Wiklund O: Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2761-2767.
• [23]Wallberg-Jonsson S, Cederfelt M, Rantapaa-Dahlqvist S: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000, 27:71-75.
• [24]Svenson KL, Lithell H, Hallgren R, Vessby B: Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 1987, 147:1917-1920.